(PRWEB) May 10, 2013
Swiss based company, Corena Therapeutics has launched Coresatin in Pharmagora fair Paris at 6-8th April that was attended by leading dermatologists, doctors, physicians and leaders of industry from all over the world. Pharmagora 2013 hosted international dignitaries of pharmacists, doctors, industry leaders and saw the participation of more than 400 exhibitors and over 26.000 professionals from all over the world. The event has focused on the changing trends in pharmaceutical industry and latest products coming into the market. Corena Therapeutics used this fair as the launching pad to unveil its Coresatin brand consisting of highly customized products that optimize the therapeutic performance without the undesired side effects.
Upon WHO reports, skin disease is not a leading cause of mortality, it is not usually thought of as a major health issue in developing countries. However, it is extremely common; up to 21-87% of the population may be affected by some type of skin problem, depending on the locale. It also contributes to significant physical and psychological disabilities. These disabilities have been measured by a number of life quality measures, but the importance of skin health is often underestimated because of the chronic, non-life threatening nature of most skin diseases. Disfigurement and discomfort associated with skin problems make them among the main reasons people seek medical care, and are the cause of approximately 24% of primary care visits. Skin diseases in developing countries have a serious impact on people's quality of life, causing lost productivity at work and school, and discrimination due to disfigurement. Skin changes may also indicate the presence of more serious diseases that need treatment. In the past, such conditions were ignored or given low priority by health authorities because they did not, on the whole, kill people, and they often did not present in tertiary care centers. But now there is a big push at both national and international levels to train health workers in developing countries to improve diagnosis and treatment of dermatological conditions.
This product launch is aimed at securing a robust market presence where there are a lot of existing players. According to the executives, Coresatin products are used to treat several inflammatory skin disorders like psoriasis, dermatitis, eczema and other severe conditions like diabetic foot ulcers and fungal infections. Products are being marketed in US and Europe, to provide effective relief to those who are suffering from complex skin barrier dysfunctionality and other related conditions. Corena Therapeutics executives also claims that they are presenting innovative and safe alternatives to available treatments. The company focus on designing highly customized products that optimize the therapeutic performance without the undesired side effects and believe that these innovations will have great impact on improving human health.
About the Company
Corena Therapeutics is an emerging company dedicated to the development of novel products that will improve the quality of life in the field of dermatology. With a unique approach to skin disorders Corena Therapeutics’ mission is to present innovative and safe alternatives to available treatments. All the efforts focus on designing highly customized products that optimize the therapeutic performance without the undesired side effects. The strong scientific knowledge of distinguished team of scientists with a diverse scientific background and expertise come to life with innovative product developments and these innovations will have a great impact on improving human health.
Read the full story at http://www.prweb.com/releases/2013/5/prweb10721452.htm.
Copyright©2012 Vocus, Inc.
All rights reserved